NASDAQ:QTTB Q32 Bio (QTTB) Stock Price, News & Analysis $8.36 -0.12 (-1.36%) Closing price 11/20/2026 03:58 PM EasternExtended Trading$8.35 -0.02 (-0.18%) As of 11/20/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Q32 Bio Stock (NASDAQ:QTTB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Q32 Bio alerts:Sign Up Key Stats Today's Range$8.22▼$8.5950-Day Range$7.52▼$11.1752-Week Range$1.93▼$23.57Volume476,717 shsAverage Volume360,355 shsMarket Capitalization$250.28 millionP/E Ratio2.50Dividend YieldN/APrice Target$32.17Consensus RatingModerate Buy Company Overview Q32 Bio is a biotechnology company focused on developing treatments for autoimmune and inflammatory diseases by targeting pathways that regulate the immune system. Its research has centered on biologic medicines designed to restore immune balance and address disease mechanisms. The company’s programs have included ADX-097, a complement C3 inhibitor designed to target activity in affected tissues, and ADX-914, an antibody targeting the interleukin-7 receptor alpha. Q32 Bio has been based in the United States and has advanced its programs through clinical development. Q32 Bio became a publicly traded company in 2024 through a business combination with Homology Medicines. The combined company retained the Q32 Bio name and trades on the Nasdaq under the symbol QTTB.AI Generated. May Contain Errors. Read More Q32 Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks74th Percentile Overall ScoreQTTB MarketRank™: 3.70478170478 of 5 starsQ32 Bio scored higher than 74% of companies evaluated by MarketBeat, and ranked 139th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingQ32 Bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 1 strong buy rating, 6 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialQ32 Bio has a consensus price target of $32.17, representing about 284.5% upside from its current price of $8.37.Amount of Analyst CoverageQ32 Bio has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Q32 Bio's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Q32 Bio are expected to decrease in the coming year, from ($1.42) to ($1.83) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Q32 Bio is 2.50, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.27.Price to Earnings Ratio vs. SectorThe P/E ratio of Q32 Bio is 2.50, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 32.60.Price to Book Value per Share RatioQ32 Bio has a P/B Ratio of 0.87. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted28.50% of the float of Q32 Bio has been sold short.Short Interest Ratio / Days to CoverQ32 Bio has a short interest ratio ("days to cover") of 12.13, which indicates bearish sentiment.Change versus previous monthShort interest in Q32 Bio has recently decreased by 1.10%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldQ32 Bio does not currently pay a dividend.Dividend GrowthQ32 Bio does not have a long track record of dividend growth. News and Social Media2.7 / 5News Sentiment0.34 News SentimentQ32 Bio has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Q32 Bio this week, compared to 3 articles on an average week.Search Interest5 people have searched for QTTB on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.MarketBeat Follows1 people have added Q32 Bio to their MarketBeat watchlist in the last 30 days. Company Ownership1.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Q32 Bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $320,397.00 in company stock.Percentage Held by Insiders34.46% of the stock of Q32 Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions31.32% of the stock of Q32 Bio is held by institutions.Read more about Q32 Bio's insider trading history. Receive QTTB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Q32 Bio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. QTTB Stock News HeadlinesQ32 Bio Inc. (QTTB) - What Are Analysts Thinking About This Stock?November 17, 2026 | americanbankingnews.comHead-To-Head Review: Q32 Bio (QTTB) versus Its CompetitorsNovember 16, 2026 | americanbankingnews.comYour Copy is on Hold (Claim it now)James Altucher, who called NVIDIA in 2008 and SpaceX years before a single share traded, has a new report on Elon Musk's next big industry play. He estimates it could create 1.8 million new millionaires in the coming years, and shows how to position in the company at its center for under $60. Inside: the company's name and ticker, plus an FCC filing James believes reveals Elon's plan to take over a $25 trillion industry. He also flags December 8 as a key date.November 21 at 1:00 AM | Paradigm Press (Ad)Q32 Bio to Participate in the 2026 Jefferies Global Healthcare Conference in LondonNovember 11, 2026 | prnewswire.comQ32 Bio Reports Q3 Results; Advances Bempikibart Toward Phase 3 In Alopecia AreataNovember 4, 2026 | rttnews.comQ32 Bio Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateNovember 4, 2026 | prnewswire.comLeerink Partners initiates coverage of Q32 Bio with outperformOctober 13, 2026 | msn.comJefferies Keeps Their Buy Rating on Q32 Bio (QTTB)October 3, 2026 | theglobeandmail.comSee More Headlines QTTB Stock Analysis - Frequently Asked Questions How have QTTB shares performed this year? Q32 Bio's stock was trading at $3.32 on January 1st, 2026. Since then, QTTB shares have increased by 152.0% and is now trading at $8.3650. How were Q32 Bio's earnings last quarter? Q32 Bio Inc. (NASDAQ:QTTB) announced its quarterly earnings results on Wednesday, November, 4th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.33) by $0.07. When did Q32 Bio IPO? Q32 Bio (QTTB) raised $135 million in an initial public offering (IPO) on Wednesday, March 28th 2018. The company issued 9,000,000 shares at $14.00-$16.00 per share. Who are Q32 Bio's major shareholders? Top institutional investors of Q32 Bio include American Century Companies Inc. (2.18%), Baker BROS. Advisors LP (1.83%), Marshall Wace LLP (1.23%) and Goldman Sachs Group Inc. (0.96%). Insiders that own company stock include Orbimed Advisors Llc, Diyong Xu, Jodie Pope Morrison, Lee Kalowski, Shelia M Violette and Paul Alloway. View institutional ownership trends. How do I buy shares of Q32 Bio? Shares of QTTB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Q32 Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Q32 Bio investors own include NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Broadcom (AVGO), Cameco (CCJ), Pfizer (PFE), Barrick Mining (B) and BigBear.ai (BBAI). Company Calendar Last Earnings11/04/2026Today11/21/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 QTTB's financial health is in the Yellow zone, according to TradeSmith. QTTB has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:QTTB Previous SymbolNASDAQ:QTTB CIK1661998 Webwww.q32bio.com Phone(781) 999-0232FaxN/AEmployees25Year FoundedN/APrice Target and Rating Average Price Target for Q32 Bio$32.17 High Price Target$40.00 Low Price Target$14.00 Potential Upside/Downside+284.5%Consensus RatingModerate Buy Rating Score (0-4)2.78 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)$3.34 Trailing P/E Ratio2.50 Forward P/E RatioN/A P/E GrowthN/ANet Income$29.82 million Net MarginsN/A Pretax Margin60.02% Return on Equity17.03% Return on Assets15.24% Debt Debt-to-Equity RatioN/A Current Ratio56.34 Quick Ratio56.34 Sales & Book Value Annual Sales$53.74 million Price / Sales4.66 Cash Flow$1.53 per share Price / Cash Flow5.47 Book Value$9.61 per share Price / Book0.87Miscellaneous Outstanding Shares29,920,000Free Float19,612,000Market Cap$250.28 million OptionableOptionable Beta0.45 The 7 Best High-Yield Dividend Stocks for 2027Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.Get This Free Report This page (NASDAQ:QTTB) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored432 miles southeast of Washington, DC…Spruce Pine, North Carolina, a town of just over 2,000 people, has supplied a material to every major chip mak...Wall Street Watchdogs | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Q32 Bio Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Q32 Bio With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.